The complexity of PTEN: Mutation, marker and potential target for therapeutic intervention

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 537-550

  Steelman, Linda S ^a   Bertrand, Fred E ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer; Phosphatase and tensin homologue deleted on chromosome 10 (PTEN); Phosphoinositide 3 kinase (PI3K) Akt; Signal transduction; Therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; IMATINIB; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOSIDE ANALOG; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; WORTMANNIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRONCHITIS; CARCINOGENESIS; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COWDEN SYNDROME; DOSE RESPONSE; ENDOMETRIUM CANCER; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MODEL; HUMAN; LUNG CANCER; LUNG DISEASE; NONHUMAN; OVARY CANCER; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL NUCLEUS; FEMALE; GENES, TUMOR SUPPRESSOR; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; LUNG DISEASES; MALE; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHOLIPIDS; PHOSPHOPROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 11144310076     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.537     Document Type: Review

References (112)

1. ENG C: PTEN: One gene, many syndromes. Hum. Mutat. (2003) 22:183-198.
2. HILL C, HUNTER SB, BRAT DJ: Genetic markets in glioblastoma: prognostic significance and future therapeutic implications. Adv. Anat. Pathol. (2003) 10:212-217.
3. SHERBET GV, PATIL D: Genetic abnormalities of cell proliferation, invasion and metastasis, with special reference to gynecological cancers. Anticancer Res. (2003) 23:1357-1371.
4. PARSONS R, SIMPSON L: PTEN and cancer. Methods Mol. Biol. (2003) 222:147-166.
5. HARADA N, SUGIMURA T, YOSHIMURA R et al.: Novel germline mutation of the PTEN gene in a Japanese family with Cowden disease. J. Gastroenterol. (2003) 38:87-91.
6. KNOBBE CB, MERLO A, REIFENBERGER G: PTEN signaling in gliomas. Neurooncol. (2002) 4:196-211.
7. YAMADA KM, ARAKI M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. (2001) 114:2375-2382.
8. DOWNES CP, BENNETT D, MCCONNACHIE G et al.: Antagonism of PI 3-kinase-dependent signaling pathways by the tumour suppressor protein, PTEN. Biochem. Soc. Trans. (2001) 29:846-851.
9. RAFTOPOULOU M, ETIENNE-MANNEVIELLE S, SELF A et al.: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science (2004) 303:1179-1181.
10. CHANG F, LEE JT, NAVOLANIC P et al.: Involvement of the PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia (2003) 17:590-603.
11. STECK PA, PERSHOUSE MA, JASSER SA et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. (1997) 15:356-362.
12. TORRES J, PULIDO R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. (2001) 276:993-998.
13. TORRES J, RODRIGUEZ J, MYERS MP et al.: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J. Biol. Chem. (2003) 278 30652-30660.
14. MYERS MP, TONKS NK: PTEN: sometimes taking it off can be better than putting it on. Am. J. Human Genet. (1997) 61 1234-1238.
15. MAEHAMA T, DIXON JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. (1998) 273:13375-13378.
16. LI D-M, SUN H: TEP1, encoded by a candidate tumor suppressor locus is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Res. (1997) 57:2124-2129.
17. LI J, YEN C, LIAW D et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (1997) 275:1943-1947.
18. MYERS MP, STOLAROV J, ENG C et al.: P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA (1997) 94:9052-9057.
19. ZHU X, KWON CH, SCHLOSSHAUER PW et al.: PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. (2001) 61:4569-4575.
20. WENG LP, BROWN JL, ENG C: PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum. Mol. Genet. (2001)10:599-604.
21. WENG LP, BROWN JL, ENG CL: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways. Hum. Mol. Genet. (2001)10:237-242.
22. WENG LP, GIMM O, KUM JB et al.: Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum. Mol. Genet. (2001 10 251-258.
23. GINN-PEASE M, ENG C: Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with GOG1 in MCF-7 cells. Cancer Res. (2003) 63:282-286.
24. ENG C: PTEN: One gene, many syndromes. Hum. Mut. (2003) 22:183-198.
25. WAITE KA, ENG C: Protean PTEN: form and function. Am. J. Hum. Genet. (2002) 70:829-844.
26. LAUGHNER E, TAGHAVI P, CHILES K et al.: HER2 (neu signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1alpha) synthesis: novel mechanism for HIF1-mediated growth factor expression. Mol. Cell Biol. (2001) 21:3995-4004.
27. MAZURE NM, CHEN EY, LADEROUTE KR et al.: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3 kinase/Akt signaling pathway in Ha-Ras-transformed cells through a hyposia inducible factor-1 transcriptional element. Blood (1997) 90:3322-3331.
28. ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphtidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for rumor angiogenesis and therapeutics. Cancer Res. (2000) 60:1541-1545.
29. TSUGAWA K, JONES MK, SUGIMACHI K et al.: Biological role of phosphatase PTEN in cancer and tissue injury healing. Front. Biosci. (2002) 7:245-251.
30. DI CRISTOFANO A, PANDOLFI PP: The multiple roles of PTEN in tumor suppression. Cell (2000) 100:387-390.
31. MUTTER GL: PTEN, a protean tumor suppressor. Am. J. Pathol. (2001) 158:1895-1898.
32. TROUSSARD AA, MAWJI NM, ONG C et al.: Conditional knock-out of integrin-linked kinase demonstrates and essential role in protein kinase B/Akt activation. J. Biol. Chem. (2003) 278 22374-22378.
33. STEELMAN LS, POHNERT SC, SHELTON JG et al.: JAK/STAT, RAF/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 18:189-218.
34. RODRIGUES GA, FALASCA M, ZHANG Z et al.: A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol. (2000) 20:1448-1459.
35. MAHIMAINATHAN L, CHOUDHURY GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J. Biol. Chem. (2004) 279:15258-15268.
36. MYERS MR, PASS I, BATTY IH et al.: The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA (1998) 95:13513-13518.
37. STEELMAN LS, POHNERT SC, SHELTON JG et al.: JAK/STAT, RAF/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 18:189-218.
38. VAZQUEZ F, GROSSMAN SR, TAKAHASHI SR et al.: Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. (2001) 276:48627-48630.
39. WENG LP, SMITH WM, BROWN JL et al.: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum. Mol. Genet. (2001) 10:605-616.
40. WENG LP, BROWN JL, BAKER KM et al.: PTEN blocks insulin-mediated Ets-2 phosphorylation through MAP kinase, independent of the phosphoinositide-3-kinase pathway. Hum. Mol. Genet. (2002) 11:1687-1696.
41. SIMPSON L, LI J, LIAW D et al.: PTEN expression causes a feedback upregulation of IRS-2 signaling. Mol. Cell Biol. (2001) 21:3947-3958.
42. KAU TR, SCHROEDER F, RAMASWAMY S et al.: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell (2003) 4:463-476.
43. NELSON MR, VAN STAVERN CG, PEETERS EA et al.: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. (1997) 6:1383-1387.
44. MARSH DJ, COULON V, LUNETTA KL et al.: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. (1998) 7:507-515.
45. ROBINSON S, COHEN AR: Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis. Neurosurgery (2000) 46:371-383.
46. ZORI RT, MARSH DJ, GRAHAM GE et al.: Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am. J. Med. Genet. (1998) 80:399-402.
47. KWAK YG, SONG CH, YI HK et al.: Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J. Clin. Invest. (2003) 111:1083-1092.
48. SORIA JC, LEE HY, LEE JI et al.: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. (2002) 5:1178-1184.
49. SALVESEN HB, MACDONALD N, RYAN A et al.: PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer (2001) 91 22-26.
50. KANG YH, LEE HS, KIM WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. (2002) 82:285-291.
51. TAMURA G: Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol. Histopathol. (2004) 19:221-228.
52. HERMAN JG: Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. (1999) 9:359-367.
53. RAZANI B, SCHLEGEL A, LIU J et al.: Caveolin-1, a putative tumour suppressor gene. Biochem. Soc. Trans. (2001) 29 494-499.
54. CASELLI A, MAZZINGHI B, CAMICI G et al.: Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem. Biophys. Res. Commun. (2002) 296 692-697.
55. ALDRED MA, GINN-PEASE ME, MORRISON CD et al.: Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. (2003) 63:2864-2871.
56. LI L, REN CH, TAHIR SA et al.: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. (2003) 23 9389-9404.
57. ALDRED MA, GINN-PEASE ME, MORRISON CD et al.: Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. (2003) 63:2864-2871.
58. FRISK T, FOUKAKIS T, DWIGHT T et al.: Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer (2002) 35:74-80.
59. ENG C: Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann. N Y Acad. Sci. (2002) 968:213-221.
60. GIMM O, PERREN A, WENG LP et al.: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. (2000) 156:1693-1700.
61. PARSONS R, MYEROFF LL, LIU B et al.: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. (1995) 55 5548-5550.
62. DICUONZO G, ANGELETTI S, GARCIA-FONCILLAS J et al.: Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin. Cancer Res. (2001) 7:4049-4053.
63. KUISMANEN SA, MOISIO AL, SCHWEIZER P et al.: Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am. J. Pathol. (2002) 160:1953-1958.
64. GUANTI G, RESTA N, SIMONE C et al.: Involvement of the PTEN mutations in the genetic pathways of colorectal cancerogensis. Hum. Oncol. Genet. (1999) 35:647-651.
65. SHINK H, PARK YJ, PARK JG: PTEN mutations in colorectal cancers displaying microsatellite instability. Cancer Lett. (2001) 174:189-194.
66. GOEL A, ARNOLD CN, NIEDZWIECKI D et al.: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability high sporadic colorectal cancers. Cancer Res. (2004) 64:3014-3021.
67. MAXWELL GL, RISINGER JI, TONG B et al.: Mutation of die PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol. Oncol. (1998) 70:13-16.
68. OBATA K, MORLAND SJ, WATSON RH et al.: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. (1998) 58:2095-2097.
69. SCHONDORF T, DOSTAL A, GRABMANN J et al.: Single mutations of the PTEN gene in recurrent ovarian carcinomas. J. Soc. Gynecol. Investig. (2000) 7:313-316.
70. CHENG JQ, GODWIN AK, BELLACOSA A et al.: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA (1992) 89:9267-9271.
71. BELLACOSA A, DE FEO D, GODWIN AK et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer (1995) 64:280-285.
72. THOMPSON FH, NELSON MA, TRENT JM et al.: Amplification of the 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH and molecular studies. Cancer Genet. Cytogenet. (1996) 87:55-62.
73. RISINGER JI, HAYES AK, BERCHUCK A et al.: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. (1997) 57 4736-4738.
74. TASHIRO H, BLAZES MS, WU R et al.: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. (1997) 57:3935-3940.
75. LEVINE RL, CARGILE CB, BLAZES MS et al.: PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. (1998) 58:3254-3258.
76. MAXWELL GL, RISINGER JI, TONG B et al.: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. (1998) 58:2500-2503.
77. MAIA H Jr, MALTEZ A, ATHAYDE C et al.: Detection of endometrial intraepithelial neoplasia (EIN) in postmenopausal endometrium. Maturitas (2003) 46(2):153-161.
78. STAMBOLIC V, TSAO MS, MACPHERSON D et al.: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in PTEN+/- mice. Cancer Res. (2000) 60:3605-3611.
79. KANAMORI Y, KIGAWA J, ITAMOCHI H et al.: Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. (2001) 7:892-895.
80. WAN X, YOKOYAMA Y, SHINOHARA A et al.: PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ. (2002) 9:414-420.
81. TERAKAWA N, KANAMORI Y, YOSHIDA S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer (2003) 10 203-208.
82. WU XSK, NESHAT MS, WHANG YE et al.: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinasc/Akt pathway. Proc. Natl. Acad. Sci. USA (1998) 95:15587-15591.
83. FEILOTTER HE, NAGAI MA, BOAG AH et al.: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 16:1743-1748.
84. MCMENAMIN ME, SOUNG P, PERERA S et al.: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. (1999) 59 4291-4296.
85. ZHENG XY, DING W, XIE LP et al.: Correlation of Skp2 and p27 (kip1) protein expression and clinicopathological features of prostate cancer. Ai. Zheng (2004) 23:215-218.
86. YANG G, AYALA G, DEMARZO A et al.: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. (2002) 8 3419-3426.
87. VAN BRUSSEL JP, VAN STEENBRUGGE GJ, ROMIJN JC et al.: Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur. J. Cancer (1999) 35 664-671.
88. LEE JT, STEELMAN LS, MCCUBREY JA: PI3K activation leads to MRP-1 expression and subsequent chemoresistance in advanced prostate cancer. Cancer Res. (2004) In Press.
89. GRUNWALD V, DEGRAFFENRIED L, RUSSEL D et al.: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. (2002) 62 6141-6145.
90. HUANG H, CHEVILLE JC, PAN Y et al.: PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. (2001) 276:38830-38836.
91. TIWARI G, SAKAUE H, POLLACK JR et al.: Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Mol. Cancer Res. (2003) 1:475-484.
92. DEOCAMPO ND, HUANG H, TINDALL DJ: The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. (2003) 28:145-153.
93. PERREN A, WENG LP, BOAG AH et al.: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. (1999) 155:1253-1260.
94. DAHIA PL, FITZGERALD MD, ZHANG X et al.: A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene (1998) 16:2403-2406.
95. BYUN DS, CHO K, RVU BK et al.: Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int. J. Cancer (2003) 104:318-327.
96. YOKOYAMA Y, WAN X, SHINOHARA A et al.: Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int. J. Mol. Med. (2000) 6:47-50.
97. ZYSMAN MA, CHAPMAN WB, BAPAT B: Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am. J. Pathol. (2002) 160:795-800.
98. SEHGAL SN, BAKER H, ENG CP et al.: Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. J. Antibiot. (1983) 36 351-354.
99. DANCEY JE: Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. (2002) 16 1101-1114.
100. SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of activation and immunosuppressive effects result from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biachem. (1998) 31:335-340.
101. PROUD CG, WANG X, PATEL JV et al.: Interplay between insulin and nutrients in the regulation of translation factors. Biochem. Soc. Trans. (2001) 29:541-547.
102. PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA (2001) 98 10320-10325.
103. YU K, TORAL-BARZA L, DISCAFANI C et al.: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer (2001) 8:249-258.
104. GINGRAS AC, GYGI SP, RAUGHT B et al.: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. (1999) 13:1422-1437.
105. PERALBA JM, DEGRAFFENRIED L, FRIEDRICHS W et al.: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. (2003) 9:2887-2892.
106. GU J, TAMURA M, YAMADA KM: Tumor suppressor PTEN inhibits integrin-and growth factor mediated mitogen-activated protein (MAP) kinase signaling pathways. J. Cell. Biol. (1998) 143 1375-1383.
107. TAMURA M, GU J, TAKINO T et al.: Tumor suppressor PTEN inhibition of cell invasion, migration and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. (1999) 59:442-449.
108. TAMURA M, GU J, DANEN EH et al.: PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositiol 3-kinase/Akt cell survival pathway. J. Biol. Chem. (1999) 274:20693-20703.
109. MAEHAMA T, OKAHARA F, KANAHO Y: The tumor suppressor PTEN: involvement of a tumor suppressor candidate protein in PTEN turnover. Biochem. Soc. Trans. (2004) 32:343-347.
110. NING K, PEI L, LIAO M et al.: Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J. Neurosci. (2004) 16:4052-4060.
111. PERREN A. KOMMINOTH P, SAREMASLANI P et al.: Mutation and expression analysis reveals differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. (2000) 157:1097-1103.
112. FREEMAN DJ, LI AG, WEI A et al.: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase dependent and independent mechanisms. Cancer Cell (2003) 3:117-130.